ライフサイエンスコーパス: drug abuse

1 anxiety, motivation for change, and years of drug abuse).

2 lamine signaling has long been implicated in drug abuse.

3 lapse prevention agent for multiple types of drug abuse.

4 related to the pursuit of rewards to promote drug abuse.

5 , Patterson Trust, and National Institute on Drug Abuse.

6 identify shared environmental influences on drug abuse.

7 with increased susceptibility to alcohol and drug abuse.

8 a potential pharmacotherapeutic to decrease drug abuse.

9 rmacotherapeutic target for the treatment of drug abuse.

10 n 'gateway drug' effects in animal models of drug abuse.

11 heir potential role in the predisposition to drug abuse.

12 in, oedema and rubor of right lower limb and drug abuse.

13 nd Alcoholism, and the National Institute on Drug Abuse.

14 ality, such as impulsivity, risk-taking, and drug abuse.

15 such as relapse in psychiatric disorders and drug abuse.

16 otinic systems also have well-known roles in drug abuse.

17 different brain regions following hypoxia or drug abuse.

18 flammation associated with HIV infection and drug abuse.

19 search and Quality and National Institute on Drug Abuse.

20 ced behavioral changes and susceptibility to drug abuse.

21 arning and cognitive performance relevant to drug abuse.

22 has been proposed to be an endophenotype for drug abuse.

23 ar circuitry involved in reward learning and drug abuse.

24 lie the pathophysiology of schizophrenia and drug abuse.

25 y is an intrinsic motivator for cessation of drug abuse.

26 s central nervous system disorders including drug abuse.

27 Trials Network of the National Institute on Drug Abuse.

28 ms, may be involved in aspects of reward and drug abuse.

29 n from the 1999 National Household Survey on Drug Abuse.

30 s as Parkinson's disease, schizophrenia, and drug abuse.

31 been implicated in psychiatric disorders and drug abuse.

32 se, schizophrenia, Huntington's disease, and drug abuse.

33 's disease, schizophrenia, chronic pain, and drug abuse.

34 rticipants with previous and current non-AAS drug abuse.

35 ially useful tool to sustain abstinence from drug abuse.

36 s problematic impulsive behaviour, including drug abuse.

37 ogical tools for behavioural intervention in drug abuse.

38 interventions are highly required to combat drug abuse.

39 rimary Funding Source: National Institute on Drug Abuse.

40 t R01-DA15612 from the National Institute on Drug Abuse.

41 of the cerebellum in psychiatric disease and drug abuse.

42 t role in the development and persistence of drug abuse.

43 standard method for the detection of chronic drug abuse.

44 reward are two significant risk factors for drug abuse.

45 reward system and are critically involved in drug abuse.

46 n to the opioid receptors including pain and drug abuse.

47 at have been translated to in vivo models of drug abuse.

48 Prevalences of 12-month and lifetime drug abuse (1.4% and 7.7%, respectively) exceeded rates

49 alcohol abuse (10.1% vs 3.8%, P < .001) and drug abuse (11.4% vs 6.9%, P < .01) compared with those

50 betes (26%), congestive heart failure (23%), drug abuse (20%), and hypertension (17%).

51 DSM-IV drug abuse or dependence; (2) DSM-IV drug abuse; (3) DSM-IV drug dependence; and (4) emerging

52 rders (alcohol abuse, 96.5 [0.67]; P < .001; drug abuse, 97.6 [0.64]; P = .02), and specific phobia (

53 tation was the only independent predictor of drug abuse after transplantation (P=0.017).

54 s to ART initiation, including non-injection drug abuse, alcohol abuse, and mental illness.

55 at onset </=21) subjects had higher risks of drug abuse, alcohol abuse, rapid cycling, and suicide at

56 sources of parent-offspring resemblance for drug abuse, alcohol use disorders, and criminal behavior

57 registries, the authors identified rates of drug abuse, alcohol use disorders, and criminal behavior

58 For drug abuse, alcohol use disorders, and criminal behavior

59 ming and nursing, depression and stress, and drug abuse, among others.

60 The underlying molecular mechanisms of drug abuse and addiction behaviors are poorly understood

61 rol; and misconceptions and prejudices about drug abuse and addiction contribute to this educational

62 Although environmental factors contribute to drug abuse and addiction, genetic factors also play a si

63 pigenetic landscape likely underlies chronic drug abuse and addiction.

64 can facilitate more effective treatments of drug abuse and addiction.

65 ten serve as animal vulnerability models for drug abuse and addiction.

66 in a variety of clinical disorders including drug abuse and addiction.

67 c festival, is notorious for the problems of drug abuse and addiction.

68 Distances ranged from 0.070 (between drug abuse and alcohol dependence) to 1.032 (between dru

69 Externalizing disorders-drug abuse and alcohol use disorders-demonstrated the th

70 xual behavior, aggression, circadian rhythm, drug abuse and anxiety implicate 5-HT(3A) receptors in t

71 sed to study a link between vulnerability to drug abuse and anxiety-like reactivity.

72 Twelve-month and lifetime prevalence of drug abuse and dependence and the associated correlates,

73 or more symptoms that operationalize DSM-IV drug abuse and dependence criteria.

74 To present detailed information on drug abuse and dependence prevalence, correlates, and co

75 o be associated with alcoholism and multiple drug abuse and dependence.

76 ormalities in the endocannabinoid system and drug abuse and dependence.

77 unwanted side effects and the potential for drug abuse and diversion.

78 se and alcohol dependence) to 1.032 (between drug abuse and dysthymia).

79 ave implications for our etiologic models of drug abuse and especially for contingency management pro

80 f individual and interpersonal correlates of drug abuse and health care service use were collected be

81 ystem to investigate the association between drug abuse and HIV infection in HIV-PAH development.

82 play a pathophysiologic role in anxiety and drug abuse and is a potential therapeutic target in thes

83 g given a worldwide epidemic of prescription drug abuse and its devastating socioeconomic impacts on

84 ave an important role in the early stages of drug abuse and may drive the increased drug seeking and

85 of clinical evidence on comorbidity between drug abuse and mood disorders, we used this model to inv

86 National Institute on Drug Abuse and National Institute of Allergy and Infecti

87 ty, with constraint associated with parental drug abuse and negative emotionality with parental alcoh

88 design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.

89 e a major risk factor for the development of drug abuse and other unsafe behaviors.

90 Those with concurrent drug abuse and recurrent major depressive disorder were

91 An important factor in the risk of drug abuse and relapse is stress.

92 to mediate the complex relationship between drug abuse and social bonding.

93 etion of NOP receptors confers resilience to drug abuse and support a role for NOP receptor antagonis

94 National Institute on Drug Abuse and the Lifespan/Tufts/Brown Center for AIDS

95 The National Institute on Drug Abuse and the National Institute of Mental Health f

96 National Institute on Drug Abuse and the Robert Wood Johnson Foundation.

97 opioid receptor family, is involved in pain, drug abuse, and a number of other CNS processes.

98 are impacted in age-related memory decline, drug abuse, and a wide variety of disorders, including s

99 physiology of depression, anxiety disorders, drug abuse, and alcoholism.

100 nt symptoms, and (3) early-onset recurrence, drug abuse, and crime.

101 rons has been implicated in reward learning, drug abuse, and motivation.

102 tute of Mental Health, National Institute on Drug Abuse, and National Center for Complementary and In

103 ociated comorbidities, such as dyslipidemia, drug abuse, and opportunistic infections; and lifestyle

104 te the design of novel agents to treat pain, drug abuse, and other central nervous system disorders.

105 nsion, liver disease, renal disease, illicit drug abuse, and poor performance status, but lower preva

106 rvices Administration, National Institute on Drug Abuse, and Robert Wood Johnson Foundation.

107 ates in memory for spatial tasks, relapse to drug abuse, and temporal lobe seizures.

108 H Pain Consortium, the National Institute on Drug Abuse, and the National Institute of Neurological D

109 tors for repeat IE were older age, male sex, drug abuse, and valvular replacement after an initial ep

110 In an animal model for vulnerability to drug abuse, animals that exhibit greater motor activity

111 mGlu7 function has been linked to autism, drug abuse, anxiety, and depression.

112 Similarly, those with prior drug abuse are more likely to continue drug use after tr

113 nesses, and the role of life experiences and drug abuse as causative agents in the onset of psychoses

114 ons in ERK/MAPK activity are associated with drug abuse, as well as neuropsychiatric and movement dis

115 iminished with age and with alcohol or other drug abuse, as well as reduced WM FA in the right OMPFC.

116 Recent advances in the adolescent drug abuse assessment field continue to inform clinical

117 se findings suggest an avenue for modulating drug abuse-associated changes in synaptic plasticity via

118 es of this signaling on behaviors related to drug abuse, attention, food intake, and affect.

119 Charitable Foundation, National Institute on Drug Abuse, Australian National Health & Medical Researc

120 Drug abuse before transplantation was the only independe

121 of food intake increases the acquisition of drug abuse behavior and enhances the reinforcing efficac

122 MCH also modulates sleep, drug abuse behavior, and mood, and MCH receptor antagoni

123 in multiple psychiatric disorders, including drug abuse, behavioral addictions, and eating disorders

124 factors (multiple sex partners, intravenous drug abuse, blood transfusion recipients) and chronic th

125 with mortality rates similar to suicide and drug abuse, but less than expected in the general popula

126 rivation neighborhood increased the risk for drug abuse by 2%.

127 d role in the development and maintenance of drug abuse by influencing neuronal and synaptic function

128 Drug abuse by people with severe mental disorder is a si

129 nvironmental risk factors in the etiology of drug abuse by twin sibling modeling.

130 The authors predicted concordance for drug abuse by years of co-residence until the older sibl

131 animals that were trained to self-administer drugs abused by humans.

132 y is indeed a strong intrinsic motivator for drug abuse cessation.

133 In the National Institute on Drug Abuse Collaborative Cocaine Treatment Study, which

134 US National Institute on Drug Abuse, Columbia University Mailman School of Public

135 ortion of the shared environmental effect on drug abuse comes from community-wide rather than househo

136 -administer opioids, and previous history of drug abuse comorbid with chronic pain promotes higher ra

137 However, the precise mechanisms by which drug abuse compromises the host immune defense to pulmon

138 Drug abuse continues to be a major problem facing our so

139 Chronic drug abuse, craving, and relapse are thought to be linke

140 crime in not-lived-with parents and by AUD, drug abuse, crime, and premature death in stepparents.

141 Prior research suggests that drug abuse (DA) is strongly influenced by both genetic a

142 Drug abuse (DA) strongly runs in families.

143 of PD and to clarify its effects on risk of drug abuse (DA).

144 A known to play a role in neuroadaptation to drug abuse, decreased luciferase expression when compare

145 RIMARY FUNDING SOURCE: National Institute on Drug Abuse, Department of Veterans Affairs, and National

146 Alcohol dependence and drug abuse/dependence had substantial disorder-specific

147 ad strongest loadings on alcohol dependence, drug abuse/dependence, adult antisocial behavior, and co

148 nxiety disorder, phobia, alcohol dependence, drug abuse/dependence, adult antisocial behavior, and co

149 dence; alcohol abuse/dependence; and illicit drug abuse/dependence.

150 ntion deficit hyperactivity disorder (ADHD), drug abuse, depression, and Parkinson's disease (PD).

151 Relapsing to drug abuse despite periods of abstinence and sincere att

152 risk factors for the common psychiatric and drug abuse disorders in men and women is very similar.

153 ls with no comorbid psychiatric, medical, or drug abuse disorders were scanned following 2 weeks of o

154 The outcome of opioid misuse was defined as drug abuse, drug misuse, aberrant drug-related behavior,

155 mothers had a greater reduction in risk for drug abuse during pregnancy (odds ratio=0.40, 95% CI=0.3

156 d within-person analyses of registration for drug abuse during pregnancy among Swedish women born bet

157 Because the drug abuse epidemic and the HIV-1 epidemic are closely i

158 ntagonists are effective in animal models of drug abuse, especially in models of relapse.

159 Drug abuse, especially with designer drugs, continues to

160 Drug abuse exacerbates HAND, but the mechanism(s) by whi

161 education and without a cohabiting, actively drug-abusing father.

162 elieved to contribute to multiple aspects of drug abuse, from preexisting vulnerability in at-risk in

163 BD with vs without lifetime alcohol or other drug abuse had significantly decreased FA in the left un

164 Since 1997 the US National Institute on Drug Abuse has advocated a brain disease model of addict

165 During the last few years, drug abuse has risen to the point that almost 20 million

166 reated pain and the epidemic of prescription drug abuse have coincided, creating a need for medical a

167 ication in macrophages and indicate that the drug abuse-heightened levels of central nervous system d

168 ge, education, depression, anxiety, or other drug abuse history between the HIV-positive and HIV-nega

169 Its modulation by drug abuse, however, has received very little attention.

170 DLS is known to be disrupted after chronic drug abuse; however, it remains unclear what neural sign

171 Learning is a critical aspect of drug abuse; however, it remains unclear whether drug-ass

172 icy announced its plan to fight prescription drug abuse in 2011 and unveiled the Risk Evaluation and

173 older sibling turned 21 and risk for future drug abuse in adolescents living with parental figures a

174 indings extend our understanding of risk for drug abuse in individuals with poor inhibitory control a

175 model predicted substantial heritability for drug abuse in males (55%) and females (73%), with enviro

176 was examined individually, hazard rates for drug abuse in offspring of parents with drug abuse were

177 The estimated odds ratio for drug abuse in pregnancy-discordant monozygotic twins was

178 gonist is the most common strategy to manage drug abuse in pregnant women.

179 One approach to decrease drug abuse in sports would be to accept that there is a

180 schizophrenia, and the cognitive sequelae of drug abuse in which perseveration is prominent.

181 Risk for drug abuse in women is substantially reduced during preg

182 ical reactions to stress, anxiety, mood, and drug abuse, in addition to feeding behaviors.

183 erization of drug-related decision making in drug abuse, including effects of psychological and pharm

184 , the probability of sibling concordance for drug abuse increased 2%-5%.

185 Prevalence of drug abuse increased among younger birth cohorts (4.2%,

186 n of candidate antiviral therapies targeting drug-abusing individuals.

187 Moreover, because enhanced D1R signaling in drug abuse induces changes in spine density in striatum,

188 y was conducted at the National Institute on Drug Abuse Intramural Research Program outpatient magnet

189 Drug abuse is a major risk factor for contracting HIV in

190 Drug abuse is a worldwide health concern in which addict

191 n-individual analyses indicate that risk for drug abuse is also substantially reduced in the postpart

192 Drug abuse is an etiologically complex syndrome strongly

193 ective registry data, the authors found that drug abuse is highly heritable.

194 Adolescent drug abuse is hypothesized to increase the risk of drug

195 e over activity in this pathway, its role in drug abuse is less defined.

196 Drug abuse is often initiated as a maladaptive mechanism

197 orders (HAND) caused by HIV-1 virotoxins and drug abuse is the lack of understanding the underlying m

198 Intravenous drug abuse (IVDA) is a known risk factor for endogenous

199 oons using a standard paradigm for assessing drug abuse liability; nor was any place preference found

200 euroimmune mechanisms that may contribute to drug-abuse liability, exploring evidence from opioids, a

201 re an alternative reliable method to confirm drug abuse may be required.

202 Increases in stimulant drug abuse may increase the rate of hospital admissions

203 he development of long-acting analgesics and drug abuse medication.

204 analogues with higher potency and utility as drug abuse medications.

205 ral and psychiatric vulnerabilities, such as drug abuse, mood disorders, and schizophrenia.

206 c disorders (especially anxiety disorders or drug abuse), more general medical disorders, and lower b

207 hite), 52 resulting from suicide (n = 31) or drug abuse (n = 21) and 64 probably or likely attributab

208 of Mental Health, the National Institute on Drug Abuse, NARSAD (Early Career Award), and the William

209 National Institute on Drug Abuse, National Institutes of Health, and Departmen

210 derstanding their impact on vulnerability to drug abuse, neuropsychiatric diseases with differential

211 The National Institute on Drug Abuse (NIDA) is designated as the sole legal produc

212 ere also more likely to have higher risks of drug abuse (odds ratio=11.62, 95% CI=2.16-62.66).

213 ustice programs have shown such promise with drug-abusing offenders.

214 ve episode, alcohol abuse or dependence, and drug abuse or dependence (adjusted relative risk, 2.7; 9

215 ma only) was associated with excess risk for drug abuse or dependence (adjusted relative risk, 4.9; 9

216 15.12), and were less likely to have current drug abuse or dependence (OR, 0.29; 95% CI, 0.90 to 0.92

217 lsive disorder), substance use disorder (ie, drug abuse or dependence and alcohol abuse or dependence

218 lso had a greater adjusted relative risk for drug abuse or dependence compared with subjects exposed

219 3-5 chronic kidney disease (CKD), alcohol or drug abuse or dependence diagnosis, and anemia.

220 isk for the onset of nicotine dependence and drug abuse or dependence in persons with PTSD, but no in

221 choactive substance use disorder (alcohol or drug abuse or dependence) has been consistently reported

222 g" (nicotine dependence, alcohol dependence, drug abuse or dependence, and adult antisocial behavior)

223 abuse or dependence, and 6.7% vs. 17.6% for drug abuse or dependence.

224 ncluding being without history of alcohol or drug abuse or dependence.

225 e use disorders, such as alcohol and illicit drug abuse or dependence.

226 ow-up assessments, newly incident (1) DSM-IV drug abuse or dependence; (2) DSM-IV drug abuse; (3) DSM

227 d individuals diagnosed (without intravenous drug abuse or hepatitis C infection) (n = 3205), and a b

228 tients on methadone maintenance therapy at a drug abuse outpatient center.

229 rapeutic interventions for disorders such as drug abuse, overeating, or pathological gambling.

230 Despite the likely role of GLU release in drug abuse pathology, there is no information that links

231 ease, anesthesiologists must learn to detect drug abusing patients and avoid known interactions.

232 idered a potential target for development of drug abuse pharmacotherapies, especially for alcoholism,

233 Consequently, although drug abuse policy should focus on limiting supplies of p

234 ease and meningitis in the immunocompromised drug abuse population.

235 phisms (R6G;E42G) within the HTR2B gene in a drug-abusing population, we assessed whether these polym

236 als (RCTs) of universal, middle school-based drug abuse prevention curricula are the most useful indi

237 s hindered the effectiveness of school-based drug abuse prevention curricula overall.

238 The alternative approach of using drug abuse prevention resources on treatment and demand-

239 n: childhood sexual abuse, conduct disorder, drug abuse, prior history of major depression, and dista

240 edicine, and psychiatry have higher rates of drug abuse, probably related to the high-risk environmen

241 ears of education and lower among those with drug abuse problems, outpatient medical service utilizat

242 ffspring was significantly predicted by AUD, drug abuse, psychiatric illness, and crime in not-lived-

243 Patients had no history of drug abuse, psychosis, dementia/neurodegenerative diseas

244 Drug abuse recorded in medical, legal, or pharmacy regis

245 Drug abuse recorded in medical, legal, or pharmacy regis

246 MAIN OUTCOME MEASURES: Drug abuse recorded in medical, legal, or pharmacy regis

247 portant difference between overeating versus drug abuse refers to the sensory stimulation of oral rec

248 a profile of interest for the development of drug abuse relapse prevention therapies or antidepressan

249 treating substance dependence and preventing drug abuse relapse.

250 romote the development of certain aspects of drug abuse-related behavior.

251 nd psychological specificity in the locus of drug abuse-related cognitive dysfunction.

252 Cocaine is the leading cause for drug-abuse-related visits to emergency departments, most

253 Effective medications for drug abuse remain a largely unmet goal in biomedical sci

254 of HIV-associated neurological disorder and drug abuse, remains essentially unknown.

255 vel emerging aquatic models in translational drug abuse research and small molecule screening.

256 NPS receptors may be an important target for drug abuse research and treatment and that CRF(1) mediat

257 hiatric clinical studies, including those in drug abuse research, often provide data that are challen

258 ditis, typically associated with intravenous drug abuse, rheumatic heart disease, prosthetic heart va

259 ngency management programs seeking to reduce drug abuse risk.

260 In the self-administration model of drug abuse, Ro 61-8048 reduced the rewarding effects of

261 ne in-treatment sample) and determined their drug abuse status at follow-up 12 months later.

262 on of this protein-based treatment for other drug abuse syndromes.

263 l flow assays (LFAs) are an ideal choice for drug abuse testing favored by their practicability, port

264 at there may be more complex consequences of drug abuse than current theories have explored, especial

265 Although more drug abuse than mental health subjects reported drug use

266 versions of the National Household Survey of Drug Abuse, the Youth Risk Behavior Survey (YRBS), the B

267 e in the SAMHSA National Household Survey on Drug Abuse: the Composite International Diagnostic Inter

268 ical siblings who have no history of chronic drug abuse; these findings support the idea of an underl

269 ocesses in vivo, including those relevant to drug abuse, thus providing a potential mechanistic basis

270 Although it is more common for drug abuse to progress from tobacco to cannabis, in many

271 ltisite study, conducted within the National Drug Abuse Treatment Clinical Trials Network, comparing

272 Aggressive drug abuse treatment immediately after a first psychiatr

273 A promising strategy for drug abuse treatment is to accelerate the drug metabolis

274 ave not been widely implemented in community drug abuse treatment settings.

275 selectivity and for the development of novel drug abuse treatments.

276 examine the potential of these compounds as drug-abuse treatments, we extended the previous assessme

277 One approach to treating drug abuse uses antidrug antibodies to immunize subjects

278 In animals and humans, vulnerability to drug abuse varies among individuals.

279 US National Institute on Drug Abuse; Veterans Administration.

280 may contribute to individual differences in drug abuse vulnerability and that these are likely attri

281 he known protective effects of enrichment on drug abuse vulnerability.

282 (CREM) in mediating impulsivity relevant to drug abuse vulnerability.

283 ore novel neurobiological systems underlying drug abuse vulnerability.

284 delay discounting procedure is predictive of drug abuse vulnerability; however, the shared underlying

285 Drug abuse was assessed from medical, criminal, and phar

286 Drug abuse was defined using public medical, legal, or p

287 e negative association between pregnancy and drug abuse was moderately stronger in cousins (odds rati

288 Risk for drug abuse was predicted both by family socioeconomic st

289 idity, depressive symptoms, and prescription drug abuse were also independently associated with frail

290 When age, socioeconomic status, and drug abuse were controlled for, hazard ratios declined o

291 disorder, hearing difficulty, or history of drug abuse were excluded.

292 for drug abuse in offspring of parents with drug abuse were highest for mothers (2.80, 95% CI=2.23-3

293 In the population, rates of drug abuse were lower during pregnancy (unadjusted odds

294 eficiency anemia, obesity, alcohol abuse, or drug abuse) were associated with higher odds for hospita

295 hysicians should be highly inquisitive of IV drug abuse when presented with cases of TMA.

296 nsequences, such as depression and increased drug abuse, which, in turn, contribute to HIV transmissi

297 Within individuals, the odds ratio for drug abuse while pregnant compared with an equivalent pr

298 disorder and aggregates, possibly along with drug abuse, within families.

299 d illicit drug use (3.3% vs. 0.6% males with drug abuse, Z=2.04, p<0.05; 2.6% vs. 0.1% females with d

300 , Z=2.04, p<0.05; 2.6% vs. 0.1% females with drug abuse, Z=5.36, p<0.001; 3.4% vs. 1.1% males with dr